Development and Characterization of Folic Acid-Conjugated Amodiaquine-Loaded Nanoparticles–Efficacy in Cancer Treatment

Author:

Parvathaneni Vineela1ORCID,Shukla Snehal K.1,Gupta Vivek1ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA

Abstract

The objective of this study was to construct amodiaquine-loaded, folic acid-conjugated polymeric nanoparticles (FA-AQ NPs) to treat cancer that could be scaled to commercial production. In this study, folic acid (FA) was conjugated with a PLGA polymer followed by the formulation of drug-loaded NPs. The results of the conjugation efficiency confirmed the conjugation of FA with PLGA. The developed folic acid-conjugated nanoparticles demonstrated uniform particle size distributions and had visible spherical shapes under transmission electron microscopy. The cellular uptake results suggested that FA modification could enhance the cellular internalization of nanoparticulate systems in non-small cell lung cancer, cervical, and breast cancer cell types. Furthermore, cytotoxicity studies showed the superior efficacy of FA-AQ NPs in different cancer cells such as MDAMB-231 and HeLA. FA-AQ NPs had better anti-tumor abilities demonstrated via 3D spheroid cell culture studies. Therefore, FA-AQ NPs could be a promising drug delivery system for cancer therapy.

Funder

College of Pharmacy and Health Sciences (CPHS), St. John’s University

Doctoral Fellowship offered by the College of Pharmacy and Health Sciences at St. John’s University

NIH Academic Research Enhancement Award

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference59 articles.

1. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016–2021;Benjamin;JAMA Netw. Open,2022

2. Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives;Zhong;Signal Transduct. Target. Ther.,2021

3. Small molecules, big impact: 20 years of targeted therapy in oncology;Bedard;Lancet,2020

4. (2023, March 03). Limitations of Current Chemotherapy Regimes and Rising Incidence of Cancer Driving Growth of Support Therapies. Available online: https://www.thepharmaletter.com/article/limitations-of-current-chemotherapy-regimes-and-rising-incidence-of-cancer-driving-growth-of-support-therapies.

5. Overcoming cancer therapeutic bottleneck by drug repurposing;Zhang;Signal Transduct. Target. Ther.,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3